Format

Send to

Choose Destination
PLoS Biol. 2012;10(11):e1001433. doi: 10.1371/journal.pbio.1001433. Epub 2012 Nov 27.

Regulation of early adipose commitment by Zfp521.

Author information

1
Division of Endocrinology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.

Abstract

While there has been significant progress in determining the transcriptional cascade involved in terminal adipocyte differentiation, less is known about early events leading to lineage commitment and cell fate choice. It has been recently discovered that zinc finger protein 423 (Zfp423) is an early actor in adipose determination. Here, we show that a close paralog of Zfp423, Zfp521, acts as a key regulator of adipose commitment and differentiation in vitro and in vivo. Zfp521 exerts its actions by binding to early B cell factor 1 (Ebf1), a transcription factor required for the generation of adipocyte progenitors, and inhibiting the expression of Zfp423. Overexpression of Zfp521 in cells greatly inhibits adipogenic potential, whereas RNAi-mediated knock-down or genetic ablation of Zfp521 enhances differentiation. In addition, Zfp521⁻/⁻ embryos exhibit increased mass of interscapular brown adipose tissue and subcutaneous white adipocytes, a cell autonomous effect. Finally, Ebf1 participates in a negative feedback loop to repress Zfp521 as differentiation proceeds. Because Zfp521 is known to promote bone development, our results suggest that it acts as a critical switch in the commitment decision between the adipogenic and osteogenic lineages.

PMID:
23209378
PMCID:
PMC3507953
DOI:
10.1371/journal.pbio.1001433
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

One author (PA) is employed by a commercial entity (AstraZeneca), but there are no restrictions put by this company to publish this work or make data or materials available.

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center